<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433104</url>
  </required_header>
  <id_info>
    <org_study_id>VinmecISC1916</org_study_id>
    <nct_id>NCT04433104</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Evaluating the Safety and Efficacy of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cell Transplantation for Patients With Chronic Obstructive Pulmonary Disease (COPD) - Phase 1/2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Research Institute of Stem Cell and Gene Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Research Institute of Stem Cell and Gene Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells
      transplantation in patients with COPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of human umbilical cord
      mesenchymal stem cells in 40 patients with COPD at Vinmec International Hospital, Hanoi,
      Vietnam
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">February 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Incidence of the adverse events or serious adverse events after transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Forced Expiratory Volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mMRC</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Breathlessness scale: Modified Medical Research Council</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (CAT/SGRQ)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Georges Respiratory Questionnaire (SGRQ) or COPD Assessment Test (CAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Changes of the lung fibrosis on chest CT at 6 months, and 12 months compared with baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Treatment (UC-MSC trasnplatation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>drug therapy according to Vietnamese MOHS procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Mesenchymal Stem Cells transplantation</intervention_name>
    <description>1 x 10^6 UC-MSC per body kg will be transplanted via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation</description>
    <arm_group_label>Treatment (UC-MSC trasnplatation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug therapy according to Vietnamese MOHS procedure</intervention_name>
    <description>Salbutamol, Terbutaline</description>
    <arm_group_label>Treatment (UC-MSC trasnplatation)</arm_group_label>
    <arm_group_label>control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 40

          -  Patients with COPD stage B, C or D according to GOLD 2019

          -  Agree to join the clinical trial and sign patient consent.

        Exclusion Criteria:

          -  Patients with acute infection, cancer, cardiovascular disease, liver failure, severe
             renal failure.

          -  Patients with other lung diseases not COPD.

          -  Pregnant or lactating.

          -  Life expectancy &lt; 6 months due to concomitant illnesses.

          -  Being treated immunosuppressive drugs oral or intravenous.

          -  Patients with type II diabetes with HbA1C over 7%

          -  Currently smoking or quit smoking less than 3 months.

          -  Any medical condition, which in the opinion of the clinical investigator, would
             interfere with the treatment or outcome of the patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duc Minh Hoang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinmec Research Institute of Stem Cell and Gene Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duc Minh Hoang, PhD</last_name>
    <phone>(+84) 909 743 101</phone>
    <email>v.duchm3@vinmec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anh Hai Nguyen, MD., PhD</last_name>
    <phone>(+84)968863668</phone>
    <email>haianhnguyenbm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vinmec International Hospital Times City</name>
      <address>
        <city>Hà Nội</city>
        <state>Hanoi</state>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anh Hai Nguyen, MD, PhD</last_name>
      <phone>(+84)968863668</phone>
      <email>haianhnguyenbm@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Ribeiro-Paes JT, Bilaqui A, Greco OT, Ruiz MA, Marcelino MY, Stessuk T, de Faria CA, Lago MR. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis. 2011 Jan 1;6:63-71. doi: 10.2147/COPD.S15292.</citation>
    <PMID>21311694</PMID>
  </results_reference>
  <results_reference>
    <citation>Stessuk T, Ruiz MA, Greco OT, Bilaqui A, Ribeiro-Paes MJ, Ribeiro-Paes JT. Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years. Rev Bras Hematol Hemoter. 2013;35(5):352-7. doi: 10.5581/1516-8484.20130113.</citation>
    <PMID>24255620</PMID>
  </results_reference>
  <results_reference>
    <citation>Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MI, Taube C, Hiemstra PS. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM. 2016 May;109(5):331-6. doi: 10.1093/qjmed/hcw001. Epub 2016 Jan 27.</citation>
    <PMID>26819296</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

